Vivos Therapeutics reported Q2 2026 earnings per share of -$0.31, beating analyst expectations of -$0.42, but its revenue of $5.15 million fell short of the $5.63 million estimate. The company, focused on sleep apnea treatments, sees growing patient demand and views this quarter as a key step toward future growth. However, its financial health shows potential liquidity issues, with a low current ratio of 0.21 and negative debt-to-equity ratio of -3.18, indicating short-term financial pressure and negative shareholder equity. Investors should watch how the company manages these challenges while pursuing growth in the sleep apnea market.
Boeing is experiencing ongoing production challenges with its 737 MAX aircraft, causing delays and a recent 3.7% stock drop. Jefferies lowered its price target to $265, still implying a 32% upside from current prices, reflecting cautious optimism. Ba...
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
0G has introduced Ascend, a liquid staking product that lets users stake 0G tokens to receive a0G tokens, which can then be used to mint iAI tokens. These iAI tokens generate compute credits redeemable for AI services within the 0G ecosystem, linking...
Amazon announced a $1.9 billion investment in its Delivery Service Partner (DSP) program for 2027 to increase delivery associate pay to nearly $24 per hour and enhance safety. The company is deploying AI-powered tools like Smart Delivery Glasses and ...
Payward, the parent company of Kraken, plans to introduce HIP-3 perpetual futures markets to US traders through a permissioned structure. This move aims to provide regulated access to Hyperliquid's 24/7 perpetual futures exchange, which averaged $9 b...
